Radosavljevic, Aleksandra (56993158000)Aleksandra (56993158000)RadosavljevicAgarwal, Mamta (20833248100)Mamta (20833248100)AgarwalBodaghi, Bahram (56244598700)Bahram (56244598700)BodaghiSmith, Justine R. (7410169450)Justine R. (7410169450)SmithZierhut, Manfred (57203252974)Manfred (57203252974)Zierhut2025-06-122025-06-122020https://doi.org/10.1080/09273948.2019.1709648https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079422729&doi=10.1080%2f09273948.2019.1709648&partnerID=40&md5=ad684eb223a087818241bef736277ac4https://remedy.med.bg.ac.rs/handle/123456789/4569Introduction: Uveitic macular edema (UME) is a significant cause of visual impairment in all uveitis types. Methods: Reports that were cited in the MEDLINE database, that analyzed the effectiveness of biologics for UME in at least five patients, with a minimum follow-up of 3 months, published prior to April 1, 2019 were included. Reports that did not compare UME findings before and after the therapy, using either OCT or fluorescein angiography, were excluded. Results: Case series that analyzed the efficacy of intravitreal anti-VEGF agents showed modest, short-term benefit. Studies that investigated systemic anti-TNF agents in patients with noninfectious uveitis reported a therapeutic effect on UME. Anti-IL-6 antibodies have shown promising results for most severe cases of noninfectious UME. Interferon represents an option for patients with persistent UME in infectious and noninfectious uveitis. Conclusion: Multicenter, randomized controlled trials are needed to assess the effectiveness of each group of biologic agents in sufficient number of patients. © 2020 Taylor & Francis Group, LLC.biologic agentsinterferoninterleukin 6 inhibitormacular edemamedical therapytumor necrosis factor inhibitorsUveitisvascular endothelial growth factor